Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

News in Brief

Tracing Melanoma's Genetic Progression

DOI: 10.1158/2159-8290.CD-NB2015-173 Published February 2016
  • Article
  • Info & Metrics
  • PDF
Loading

The process by which some benign skin lesions, or nevi, transform into melanomas remains unclear. A new study illuminates the genetic evolution of melanoma and strengthens the case for a controversial category of intermediate lesions that are midway between nevi and melanomas [N Engl J Med 2015;373:1926–36].

In this study, Boris Bastian, MD, PhD, of the University of California, San Francisco, and colleagues analyzed 37 melanoma samples—each including malignant tissue and its precursor lesion—and identified 150 distinct areas that represented different stages of disease progression. They asked eight pathologists to independently classify these areas as benign, intermediate but likely benign, intermediate but likely malignant, or melanoma. Although the pathologists usually agreed on areas at the benign and melanoma ends of the spectrum, they often disagreed on areas that were in the middle.

To find out if these histologic categories carried different genetic alterations, the researchers sequenced 293 cancer-causing genes in the melanoma samples. They observed that lesions unanimously classified by the pathologists as benign had only one driver mutation, BRAF V600E. Mutations in CDKN2A and genes that encode members of the SWI/SNF complex, such as ARID1A, occurred later, followed by mutations in TP53 and PTEN.

This analysis also shed light on whether intermediate lesions represent a separate category or whether they reflect the limitations of pathologists' ability to discriminate lesion types. Bastian and colleagues found that lesions classified by at least two pathologists as intermediate were genetically distinct. Unlike benign nevi, they carried TERT mutations and either NRAS mutations or the BRAF V600K alteration.

“Our study shows that there is something between benign and malignant,” says Bastian, adding that testing for these mutations could provide a better way to distinguish such lesions. “It's a step toward an objective diagnosis of melanoma,” he says.

Essentially, lesions can follow several pathways to become melanomas, the researchers propose. Alterations that activate the MAPK pathway—BRAF V600E, BRAF V600K, or NRAS mutations—are the earliest to emerge. TERT mutations then switch on telomerase and enable the lesions to escape replicative senescence. By the time lesions have progressed to invasive melanomas, they've accrued CDKN2A mutations that disable the G1-S cell-cycle checkpoint.

“I think this is a landmark paper for melanoma,” says David Polsky, MD, PhD, of the New York University Langone Medical Center in New York City, who wasn't connected to the study. “Here, they show that there is an intermediate stage in tumor development.”

“It adds to our knowledge of the molecular events that are occurring as some melanomas develop from nevi,” says Douglas Grossman, MD, PhD, of the University of Utah Health Sciences Center in Salt Lake City.

However, before any of the mutations could be clinically useful, Grossman cautions, researchers need to determine which ones influence outcomes for patients. –Mitch Leslie

Notes

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2016 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 6 (2)
February 2016
Volume 6, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Tracing Melanoma's Genetic Progression
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Tracing Melanoma's Genetic Progression
Cancer Discov February 1 2016 (6) (2) 114; DOI: 10.1158/2159-8290.CD-NB2015-173

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Tracing Melanoma's Genetic Progression
Cancer Discov February 1 2016 (6) (2) 114; DOI: 10.1158/2159-8290.CD-NB2015-173
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • ADC Successfully Targets Urothelial Cancer
  • Break Through Cancer Launches with $250M Pledge
  • By The Numbers: Novel Drugs Approved by the FDA, 2011-2020
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement